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Abstract
Background: NAFLD impacts patient reported outcomes (PROs). Our aim was to assess the impact of NAFLD on
patients’ HRQOL.
Methods: National Health and Nutrition Examination Survey (NHANES) 2001–2011 data were used to identify adult
patients with NAFLD [Fatty Liver Index (FLI) > 60 in absence of other liver disease and excessive alcohol >20 g/day
for men, >10 g/day for women]. Patients with other chronic diseases (ex. HIV, cancer, end-stage kidney disease)
were excluded. Subjects without any of these conditions were healthy controls. HCV RNA (+) patients were
HCV-controls. All patients completed NHANES HRQOL-4 questionnaire. Linear regression determined the association
between NAFLD and HRQOL components adjusting for age, gender, race, and BMI.
Results: Participants with complete data were included (n = 9661); 3333 NAFLD (age 51 years and BMI 34 kg/m2);
346 HCV+ (age 49 years; BMI 27 kg/m2) and 5982 healthy controls (age 48 years and BMI 26 kg/m2). The proportion of
subjects rating their health as “fair” or “poor” in descending order were HCV controls (30 %) NAFLD (20 %) and healthy
controls (10 %) (p < 0.001). HRQOL-4 components scores 2–4 were lowest for HCV, followed by NAFLD and
then healthy controls (p-values p = 0.011 to < .0001). After adjustment for age, gender, race, and BMI, NAFLD
patients were 18–20 % more likely to report days when their physical health wasn’t good or were unable to
perform daily activities as a result (p < .0001).
Conclusions: NAFLD causes impairment of HRQOL. As NAFLD is becoming the most important cause of CLD,
its clinical and PRO impact must be assessed.
Background
Non-alcoholic fatty liver disease (NAFLD) is an import-
ant cause of chronic liver disease worldwide [1–5].
NAFLD has been associated with cirrhosis, hepatocellu-
lar carcinoma and is currently the second indication for
liver transplantation [6].
NAFLD is increasingly being diagnosed in patients
with nonspecific symptoms with incidental elevation
of aminotransferases [7, 8]. Besides fatigue, NAFLD
patients may also experience other symptoms such as
anxiety, depression, cognitive impairment, and loss of
self-esteem [9]. These symptoms significantly impact
patients’ well-being and health-related quality of life
(HRQOL) [10]. Although the impact of chronic hepa-
titis C infection on HRQOL has been reported exten-
sively, there is little published data about HRQOL
assessment in patients with NAFLD. Therefore, our
aim was to assess the impact of NAFLD on patients’
HRQOL as compared to HRQOL impairment in pa-
tients with CH-C and those without liver disease.* Correspondence: Zobair.younossi@inova.org
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Methods
Study design and population
Availability of data and materials: National cross-
sectional health survey data [National Health and Nu-
trition Examination Survey (NHANES) conducted be-
tween 2001 and 2011] were used. The Center for
Disease Control and Prevention (CDC) collected the
data by an interviewer-administered questionnaire
conducted in participants’ homes by trained inter-
viewers. Clinical data were obtained through the use
of specially designed and equipped mobile examin-
ation centers. Participants (n = 49,762) were excluded
if they had Alcoholic Liver Disease (ALD) (alcohol
consumption of ≥ 20 g/day for men, ≥ 10 g/day for
women over past 12 months), other chronic diseases
such as HIV, cancer, end-stage kidney disease and/or
had missing data on key variables (demographic and
HRQOL), (Fig. 1- Flow chart for Eligibility, NHANES,
2001–2012)
Sociodemographic variables
Age (years), gender, race/ethnicity (white, black,
other), education (less than high school, high school,
college or above), annual household income (less
than $55,000 per year, $55,000 or more) were self-
reported. Anthropometric measurements (height,
weight) were obtained by trained staff during the
medical examination.
Definitions of chronic liver diseases
The following liver diseases were identified and in-
cluded in the study: (1) Chronic Hepatitis C diagnosis
was based on a positive Hepatitis C antibody (ELISA
II analysis) or HCV RNA as detected by polymerase
chain reaction; (2) NAFLD was determined by the
Fatty Liver Index (FLI). A FLI score of 60 or more in
the absence of HCV, HBV and significant alcohol
consumption was NAFLD; and (3) Participants with-
out any chronic liver diseases and a FLI score ≤ 30
were considered as Healthy Controls.
Assessment of quality of life
Four components of a participants’ health-related
quality of life (HRQOL-4) over a previous 30-day
period were assessed during the scheduled visit. The
four component questions were: Component 1 (C1):
Rate your health status as poor, fair, good, very good,
or excellent. ; (b) C2 Thinking about your physical
health, which includes physical illness and injury, for
how many days during the past 30 days was your
physical health not good; (c) C3 Thinking about your
mental health, which includes stress, depression, and
problems with emotions, for how many days during
the past 30 days was your mental health not good;
and (d) C4 About how many days did poor physical
or mental health keep him/her from doing your usual ac-
tivities, such as self-care, work, or recreation.
Data analyses
For analyses, participants were divided into two groups:
fair/poor coded as “1” and good/very good/excellent
were coded as “0” for component 1. For components
C2–C4, we coded participants who reported no poor
Fig. 1 Flow chart for Eligibility, NHANES, 2001-2012
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days (50 % of participants) as “0” and coded the others
who reported any number of days >0 as “1”.
Simple logistic regression models with linearized
variance estimation and weighting were used to esti-
mate the association between self-reported quality of
life questionnaire (for each component of C1–C4,
separately) and liver disease while adjusting for age,
gender, race, BMI, smoking, education, diabetes, and
heart disease. We did not adjust household income in
the final model due to a high correlation with educa-
tion (Spearman rank-order rho = 0.40, P < .0001).
Spearman rank-order correlations were estimated to
examine an association between the participants’
ranking their health condition (C1) and demographic
variables stratified by liver disease. SAS V9.3 was used
for analyses (SAS Institute, Cary, NC). To account for
the complex survey design from NHANES, SAS sur-
vey command with sampling weight, stratification and




A total of 9661 participants with complete data were en-
rolled in the study (Table 1). Of these, 346 patients had
HCV, 3333 had NAFLD and 5982 were considered con-
trols. Mean age of the patients was 48.8 years (48.8 ±
0.50, p < .0001 in HCV, 51.3 ± 0.36, p < .0001 in NAFLD
and 47.5 ± 0.39, p < .0001 in Control). NAFLD patients
had significantly higher body mass index (BMI) as
compared to the Controls (33.66 ± 0.14 vs 26.22 ± 0.10,
p < .0001) and HCV patients (33.66 ± 0.14 vs 27.26 ±
0.41, p < .0001). Of the NAFLD cohort, 57.8 % were male
and 72.4 % were White. Furthermore, metabolic syndrome
components such as hyperlipidemia, hypertension, and
insulin resistance were more common in the NAFLD
group, as well as history of heart disease (all p < .001).
Health related quality of life in NAFLD
Component 1 of HRQOL questionnaire Component 1
of HRQOL was concerned with overall HRQOL
Table 1 Characteristics of Study by Liver Disease, NHANES, 2001–2012
Variables HCV NAFLD Control P valuea P valueb P valuec
(n = 346) (n = 3333) (n = 5982)
Age (years): mean (SE) 48.86 (0.50) 51.31 (0.36) 47.50 (0.39) 0.058 <.0001 <.0001
Body Mass Index (kg/m2): mean (SE) 27.26 (0.41) 33.66 (0.14) 26.22 (0.10) 0.037 <.0001 <.0001
Male 228 (66.87 %) 1817 (57.79 %) 3103 (50.03 %) <.0001 <.0001 0.014
Race, <.0001 0.034 <.0001
White 134 (63.53 %) 1612 (72.46 %) 3221 (75.15 %)
Black 137 (22.87 %) 684 (10.88 %) 1164 (9.50 %)
Other 75 (13.60 %) 1037 (16.66 %) 1597 (15.35 %)
Comorbid disease,
Diabetes 56 (13.03 %) 918 (20.75 %) 503 (6.05 %) <.0001 <.0001 0.010
Hyperlipidemia 177 (44.12 %) 2051 (57.01 %) 2286 (32.50 %) <.0001 <.0001 <.0001
High blood pressure 119 (29.46 %) 2020 (58.99 %) 2351 (38.35 %) 0.009 <.0001 <.0001
Insulin resistance 81 (47.34 %) 2147 (66.03 %) 442 (12.24 %) <.0001 <.0001 <.0001
Heart disease 47 (9.46 %) 540 (13.83 %) 558 (6.79 %) 0.119 <.0001 0.040
Asthma 44 (14.62 %) 394 (12.69 %) 433 (7.87 %) 0.001 <.0001 0.468
NHANES cycle, 0.135 0.696 0.152
2001–2002 71 (24.07 %) 541 (16.24 %) 1022 (16.73 %)
2003–2004 49 (16.81 %) 534 (17.15 %) 856 (15.29 %)
2005–2006 41 (13.80 %) 499 (16.98 %) 893 (16.47 %)
2007–2008 75 (18.37 %) 630 (17.07 %) 1056 (16.63 %)
2009–2010 53 (11.37 %) 602 (15.22 %) 1117 (16.74 %)
2011–2012 57 (15.58 %) 527 (17.35 %) 1038 (18.13 %)
Pvalues were reported by chi-square test for categorical variables and t-test for numerical variables;
aComparisons between HCV and Control
bComparisons between NAFLD and Control
cComparisons between HCV and NAFLD
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assessment (Table 2, Fig. 2). The proportion of partici-
pants who rated their health as excellent or very good was
significantly higher in the Control group as compared to
both NAFLD and HCV groups (90 vs 78, 68 %, respect-
ively; p < .0001). The overall HRQOL score was lowest for
HCV and then NAFLD patients.
Component 2 of HRQOL questionnaire Component 2
was mostly involved with number of days with physical
health issues. In fact, the control group was more likely to
report no days of having physical health problems com-
pared to the NAFLD group (68.3 vs 61.3 %, p < .001). On
the other hand, HCV patients were least likely to report
no days of having physical health problems (52.4 %).
Component 3 of HRQOL questionnaire Component 3
was concerned with number of days with mental
health issues. In this context, NAFLD patients reported
similar mental health issues to the controls (62.6 vs 64 %,
p > 0.05). On the other hand, HCV patients were less
likely to report no days of having mental health problem,
compared to controls and NAFLD patients (46.5 vs 62.6
and 64 %, p < 0.01).
Component 4 of HRQOL questionnaire Component
4 was concerned with number of days that the physical
and mental health issues would prevent patients from
their activities. Again, the control group had significantly
fewer number of days that physical or mental health
Table 2 HRQOL in Participants with NAFLD and HCV, NHANES, 2001–2012
Variables HCV NAFLD Control P valuea P valueb P valuec
(n = 346) (n = 3333) (n = 5982)
HRQOL-4 components,
C1, <.0001 <.0001 0.005
Excellent 20 (7.19 %) 201 (6.49 %) 863 (17.36 %)
Very good/Good 201 (60.75 %) 2112 (71.02 %) 4215 (72.22 %)
Fair 98 (24.81 %) 831 (18.83 %) 806 (9.09 %)
Poor 27 (7.24 %) 189 (3.66 %) 98 (1.32 %)
C2 (no day = 0) 187 (52.47 %) 2000 (61.34 %) 4048 (68.31 %) <.0001 <.0001 0.012
C3 (no day = 0) 175 (46.58 %) 2174 (64.07 %) 3868 (62.60 %) <.0001 0.257 <.0001
C4 (no day = 0) 230 (64.96 %) 2663 (79.84 %) 5050 (84.41 %) <.0001 <.0001 <.0001
P values were reported by chi-square test;
aComparisons between HCV and Control
bComparisons between NAFLD and Control
cComparisons between HCV and NAFLD
Fig. 2 Adjusted* mean HRQOL components (C2-C4) by liver disease, and pair-wise comparisons (t-test), NHANES, 2001–2011
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kept the participants away from doing their usual
activities (self-care, work, or recreation) during last
30-days compared to the NAFLD group (84.4 % in
the Control group reported zero effected days vs.
79.8 % in NAFLD; p < .0001). HCV patients had the
worst score with only 64.9 % in this group reporting
zero effected day (p < .0001).
After adjusting for age, gender, race, and BMI, the as-
sociation between PRO impairment and the diagnosis of
HCV (C1–C4) and NAFLD (C1, C2 and C4) remained
significant (Table 3).
(Figure 2: Adjusted* mean HRQOL components
(C2–C4) by liver disease, and pair-wise comparisons
(t-test), NHANES, 2001–2011).
Discussion
Patient reported outcomes (PROs) such as HRQOL
are surrogates for a patient’s experience [11]. Asses-
sing PROs are important to accurately estimate the
burden of chronic liver disease and its treatment on
patients’ well-being. In this study, we used
population-based data to assess HRQOL in patients
with NAFLD. Our data analysis showed that NAFLD
patients indeed experienced significant impairment of
their HRQOL. In this context, almost one fourth
(22 %) of NAFLD patients reported their health as
being poor or fair which was significantly more than
the healthy controls (10 %). Furthermore, this impair-
ment resulted in a reduction of patients’ ability to
perform their daily activities. Interestingly, NAFLD
patients had more impairment of their physical health
than their mental health. These data are partially con-
sistent with the data previously reported showing
NAFLD patients have PRO burden related to bodily
pain, shortness of breath and muscle cramps as well
as anxiety, unhappiness, being irritable and having
mood swings [12]. Furthermore, our data is consistent
with HRQOL assessment using Short Form-36 ques-
tionnaire reporting impairment in physical functioning
(how much physical activities are limited), role phys-
ical (how much physical health impacts work and
daily activities), bodily pain (limitations because of
pain), vitality (how tired/full of energy subject feels),
and role emotional (the impact of emotional problems
on work and daily activities) [13].
Although not exactly clear, the reported poor physical
health in NAFLD patients may be related to fatigue.
Fatigue has been shown in previous studies to be a sig-
nificant problem for NAFLD patients [8, 14–16]. In fact,
in one such study, autonomic dysfunction and fatigue
were both common in NAFLD [14, 17]. This could pro-
vide some mechanistic pathway for the development of
fatigue in patients with NAFLD.
It is also important to note that impairment of
HRQOL in NAFLD was less pronounced than those
with HCV. In fact, the mental health aspect of
PROs was more profoundly affected in HCV than
NAFLD. This is not a surprise given the strong as-
sociation of HRQOL with depression in patients
with HCV [18–20].
Conclusion
In conclusion, NAFLD is associated with impairment
of patients’ HRQOL. Since previous studies reporting
association of NAFLD with PRO impairment (12–13)
were reported from the tertiary care centers, their re-
sults could have been associated with referral bias.
This current study using large population database
from NHANES provides additional data documenting
impairment of HRQOL in patients with NAFLD. This
integrated approach to understanding the clinical and
PRO burden of NAFLD can provide a more compre-
hensive approach to treatment and management of
patients with NAFLD.
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Table 3 Adjusted* odds ratios (OR) with 95 % confidence intervals (CIs) for each outcome of HRQOL, NHANES, 2001-2012
(reference for C1 = excellent/very good/good and for C2–C4 = no days)
C1 C2 C3 C4
Variable OR a (95 % CI)
Control Reference Reference Reference Reference
HCV 2.07 (1.48–2.88) 1.82 (1.36–2.43) 1.98 (1.52–2.58) 2.83 (2.05–3.90)
NAFLD 1.22 (1.03–1.44) 1.18 (1.03–2.08) 0.95 (0.82–1.10) 1.20 (1.02–1.41)
a Adjusted for age, gender, race, BMI, education, income, smoking status, diabetes, and heart disease
Golabi et al. Health and Quality of Life Outcomes  (2016) 14:18 Page 5 of 7
Appendix
Abbreviations
ALD: alcoholic liver disease; BMI: body mass index; CDC: center for
disease control and prevention; CH-C: chronic Hepatitis C; CLD: chronic
liver disease; FLI: fatty liver index; HRQOL: health related quality of life;
NAFLD: nonalcoholic fatty liver disease; NHANES: National Health and
Nutrition Examination Survey; PRO: patient reported outcome.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PG participated in the study design, helped the interpretation of the
data and to draft the manuscript. MO performed the statistical analysis
and helped the interpretation of the data. MS participated in the
interpretation of the data and revised the manuscript. RC, SF and AK
made contributions to the study design as well as interpretation of the
data. ZY conceived of the study, participated substantially in its design
and coordination, and helped to draft the manuscript. All authors read
and approved the final manuscript.
Acknowledgments
We would like to thank Brian Lam and Beatty Liver & Obesity Research
Program staff for their great support during the formation of this study.
Funding
This study was internally funded without any external reimbursement, fee or
salary.
Received: 11 November 2015 Accepted: 27 January 2016
References
1. Hamaguchi M, Takeda N, Kojima T, Ohbora A, Kato T, Sarui H, et al.
Identification of individuals with non-alcoholic fatty liver disease by the
diagnostic criteria for the metabolic syndrome. World J Gastroenterol. 2012;
18:1508–16.
2. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a
practical approach to treatment. Frontline Gastroenterol. 2014;5:277–86.
3. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M,
et al. Association of Non-alcoholic Fatty Liver Disease (NAFLD) with
Hepatocellular Carcinoma (HCC) in the United States from 2004-2009.
Hepatology. 2015. doi:10.1002/hep.28123.
4. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;
313:2263–73.
5. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al.
The diagnosis and management of non-alcoholic fatty liver disease:
practice Guideline by the American Association for the Study of Liver
Diseases, American College of Gastroenterology, and the American
Gastroenterological Association. Hepatology. 2012;55:2005–23.
6. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi
ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of
liver disease among adults awaiting liver transplantation in the United
States. Gastroenterology. 2015;148:547–55.
7. Younossi ZM, Henry L. Economic and quality-of-life implications of
Non-alcoholic fatty liver disease. Pharmacoeconomics. 2015;33(12):1245–53.
doi:10.1007/s40273-015-0316-5. PMID: 26233836.
8. Newton JL. Systemic symptoms in non-alcoholic fatty liver disease. Dig Dis.
2010;28:214–9.
9. Mahmood S. Assessment of health related quality of life in chronic liver disease
patients using the Japenese versions of CLDQ and SF-36. Open Gastroenterol
J. 2008;2:57–63.
10. Loria A, Escheik C, Gerber NL, Younossi ZM. Quality of life in cirrhosis.
Curr Gastroenterol Rep. 2013;15:301.
11. Younossi ZM, Stepanova M, Nader F, Lam B, Hunt S. The patient’s
journey with chronic hepatitis C from interferon plus ribavirin to
interferon- and ribavirin-free regimens: a study of health-related quality
of life. Aliment Pharmacol Ther. 2015;42:286–95.
12. Dan AA, Kallman JB, Wheeler A, Younoszai Z, Collantes R, Bondini S,
et al. Health-related quality of life in patients with non-alcoholic fatty
liver disease. Aliment Pharmacol Ther. 2007;26:815–20.
13. Afendy A, Kallman JB, Stepanova M, Younoszai Z, Aquino RD, Bianchi G,
et al. Predictors of health-related quality of life in patients with chronic
liver disease. Aliment Pharmacol Ther. 2009;30:469–76.
14. Newton JL, Pairman J, Wilton K, Jones DE, Day C. Fatigue and autonomic
dysfunction in non-alcoholic fatty liver disease. Clin Auton Res. 2009;19:319–26.
Table 4 Spearman rho correlation for rating* their health status as poor to excellent (C1 component) with demographic variables,
stratified health conditions, NHANES, 2001–2012
rho , P
Variables Total (overall), HCV NAFLD Heart disease Diabetes
n = 9661 n = 346 n = 3333 n = 1145 n = 1477
Age (years) 0.14, <0.01 0.11, 0.03 0.10, <0.01 −0.12, <0.01 −0.06, 0.06
Body Mass Index (BMI) (kg/m2) 0.23, <0.01 0.16, 0.04 0.12, <0.01 0.16, <0.01 0.13, <0.01
Gender (1 = male and 0 = female) −0.06, <0.01 −0.11, 0.08 −0.16, <0.01 −0.12, <0.01 −0.13, <0.01
White (1 = yes and 0 = no) −0.19, <0.01 −0.10, 0.09 −0.16, <0.01 −0.20, <0.01 −0.14, <0.01
Black (1 = yes and 0 = no) 0.06, <0.01 0.08, 0.30 −0.01, 0.44 0.11, <0.01 0.02, <0.01
Other (1 = yes and 0 = no) 0.15, <0.01 0.04, 0.43 0.18, <0.01 0.13, <0.01 0.13, <0.01
C2: days physical health, which includes physical
illness and injury not good
0.30, <0.01 0.45, <0.01 0.34, <0.01 0.41, <0.01 0.39, <0.01
C3: days mental health, which includes stress,
depression, and problems with emotions not good
0.17, <0.01 0.30, <0.01 0.21, <0.01 0.28, <0.01 0.26, <0.01
C4: days poor physical or mental health keep
him/her from doing your usual activities, such
as self-care, work, or recreation not good
0.21, <0.01 0.39, <0.01 0.24, <0.01 0.28, <0.01 0.27, <0.01
*Ranges from 1 to 5 with a higher score indicates worse self-health assessment (1 = excellent; 2 = very good; 3 = good; 4 = fair; and 5 = poor)
Golabi et al. Health and Quality of Life Outcomes  (2016) 14:18 Page 6 of 7
15. Newton JL, Jones DE, Henderson E, Kane L, Wilton K, Burt AD, et al. Fatigue
in non-alcoholic fatty liver disease (NAFLD) is significant and associates with
inactivity and excessive daytime sleepiness but not with liver disease
severity or insulin resistance. Gut. 2008;57:807–13.
16. Gerber L, Otgonsuren M, Mishra A, Escheik C, Birerdinc A, Stepanova M,
et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level
of physical activity: a population-based study. Aliment Pharmacol Ther.
2012;36:772–81.
17. Kallman J, O’Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue
and health-related quality of life (HRQL) in chronic hepatitis C virus
infection. Dig Dis Sci. 2007;52:2531–9.
18. Cinar S, Ozdogan OC, Alahdab Y. Impact of education provided by nurses
on quality of life, anxiety, and depression in patients receiving hepatitis C
virus therapy. Gastroenterol Nurs. 2015;38(5):343–7.
19. Fabregas BC, de Avila RE, Faria MN, Moura AS, Carmo RA, Teixeira AL. Health
related quality of life among patients with chronic hepatitis C: a cross-
sectional study of sociodemographic, psychopathological and psychiatric
determinants. Braz J Infect Dis. 2013;17:633–9.
20. Teuber G, Schafer A, Rimpel J, Paul K, Keicher C, Scheurlen M, et al.
Deterioration of health-related quality of life and fatigue in patients with
chronic hepatitis C: Association with demographic factors, inflammatory
activity, and degree of fibrosis. J Hepatol. 2008;49:923–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Golabi et al. Health and Quality of Life Outcomes  (2016) 14:18 Page 7 of 7
